Home » Topics » Disease categories and therapies » Immune

Immune
RSS

Corixa licenses RC-529 adjuvant rights to Aventis

April 1, 2004

Innogenetics acquires Genencor's therapeutic vaccine programs

April 1, 2004

Peptimmune/Medivir Cathepsin S program designates candidate drug

March 31, 2004

FDA requests additional Homspera mouse study

March 30, 2004

Cangene to evaluate WinRho SDF for dengue hemorrhagic fever

March 25, 2004

Wyeth claims B7-1 inhibitors and their use in transplant rejection and autoimmune diseases

March 24, 2004

New data indicate mechanism of action of Immunitin

March 23, 2004

Novel Itk inhibitors with potential in immune, inflammatory and allergic disorders

March 23, 2004

Boosting endogenous interferon for hepatitis C therapy

March 23, 2004

Novel lipoxin A4 analogue with enhanced antiinflammatory activity in vivo

March 22, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...